HRP20200893T1 - Pripravci stanične kulture s antioksidansima i postupci proizvodnje polipeptida - Google Patents
Pripravci stanične kulture s antioksidansima i postupci proizvodnje polipeptida Download PDFInfo
- Publication number
- HRP20200893T1 HRP20200893T1 HRP20200893TT HRP20200893T HRP20200893T1 HR P20200893 T1 HRP20200893 T1 HR P20200893T1 HR P20200893T T HRP20200893T T HR P20200893TT HR P20200893 T HRP20200893 T HR P20200893T HR P20200893 T1 HRP20200893 T1 HR P20200893T1
- Authority
- HR
- Croatia
- Prior art keywords
- cell culture
- culture medium
- antibody
- hypotaurine
- fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 16
- 238000004113 cell culture Methods 0.000 title claims 3
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 239000003963 antioxidant agent Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000006143 cell culture medium Substances 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 11
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims 11
- 239000007788 liquid Substances 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 210000000270 basal cell Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Postupak za proizvodnju rekombinantno proizvedenog protutijela ili njegovog fragmenta, naznačen time, što on obuhvaća korak kultiviranja stanice koja sadrži nukleinsku kiselinu koja kodira protutijelo ili njegov fragment u mediju stanične kulture, pri čemu se protutijelo ili njegov fragment izlučuju u medij stanične kulture, dok medij stanične kulture sadrži hipotaurin;
te time, što medij stanične kulture koji sadrži hipotaurin, smanjuje intenzitet boje pripravka koji se sastoji od protutijela ili njegovog fragmenta, proizvedenih pomoću stanica, u usporedbi s pripravkom koji sadrži protutijelo ili njegov fragment, proizvedene pomoću stanica uzgojenih u mediju stanične kulture koji ne sadrži hipotaurin.
2. Postupak prema zahtjevu 1, naznačen time, što medij stanične kulture koji sadrži hipotaurin smanjuje intenzitet boje pripravka koji sadrži protutijelo ili njegov fragment proizvedene pomoću stanica, za najmanje oko 0,1 % u odnosu na pripravak koji sadrži protutijelo ili njegov fragment proizvedene pomoću stanica uzgojenih u mediju stanične kulture koji ne sadrži hipotaurin.
3. Postupak prema zahtjevu 1, naznačen time, što medij stanične kulture koji sadrži hipotaurin smanjuje intenzitet boje pripravka koji sadrži protutijelo ili njegov fragment proizvedene pomoću stanica, za oko 5 % do oko 50 % u odnosu na pripravak koji sadrži protutijelo ili njegov fragment proizvedene pomoću stanica uzgojenih u mediju stanične kulture koji ne sadrži hipotaurin.
4. Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, što medij stanične kulture sadrži hipotaurin u koncentraciji od najmanje oko 0,0001 mM.
5. Postupak prema patentnom zahtjevu 4, naznačen time, što medij stanične kulture sadrži hipotaurin u koncentraciji od oko 2,0 mM do oko 50,0 mM.
6. Postupak prema bilo kojem patentnom zahtjevu od 2 do 3, naznačen time, što medij stanične kulture sadrži hipotaurin
a) u koncentraciji od najmanje oko 0.0001 mM; ili
b) u koncentraciji od oko 0,0001 mM do oko 500,0 mM, ili
c) u koncentraciji od oko 1,0 mM do oko 40,0 mM; ili
d) u koncentraciji od oko 1,0 mM do oko 10,0 mM.
7. Postupak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, što je medij stanične kulture kemijski definirani medij stanične kulture.
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, što je medij stanične kulture
a) bazalni medij stanične kulture; ili
b) cjeloviti medij stanične kulture.
9. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, što je stanica u doticaju s medijem stanične kulture
a) tijekom faze rasta stanice; i/ili
b) tijekom faze proizvodnje stanice.
10. Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, što se hipotaurin dodaje u medij stanične kulture
a) barem jedan dan ciklusa stanične kulture; ili
b) na dan 0 od 14-dnevnog ciklusa stanične kulture.
11. Postupak prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, što stanica je stanica sisavaca.
12. Postupak prema patentnom zahtjevu 11, naznačen time, što stanica sisavaca je stanica jajnika kineskog hrčka (CHO).
13. Postupak prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, što protutijelo je IgG1 protutijelo.
14. Postupak prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, što nadalje sadrži korak dobivanja protutijela ili njegovog fragmenta iz medija stanične kulture koji se sastoji od jedne ili više komponenti (a)-(b).
15. Postupak prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, što je pripravak koji sadrži dobiveno protutijelo ili njegov fragment
a) tekući pripravak; i/ili
b) izgleda kao bezbojna ili blago obojena tekućina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361799602P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/029772 WO2014145098A1 (en) | 2013-03-15 | 2014-03-14 | Cell culture compositions with antioxidants and methods for polypeptide production |
EP14721668.3A EP2970875B1 (en) | 2013-03-15 | 2014-03-14 | Cell culture compositions with antioxidants and methods for polypeptide production |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200893T1 true HRP20200893T1 (hr) | 2020-09-18 |
Family
ID=50639996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200893TT HRP20200893T1 (hr) | 2013-03-15 | 2020-06-04 | Pripravci stanične kulture s antioksidansima i postupci proizvodnje polipeptida |
Country Status (19)
Country | Link |
---|---|
US (5) | US10017732B2 (hr) |
EP (2) | EP2970875B1 (hr) |
JP (2) | JP6591395B2 (hr) |
KR (2) | KR102235452B1 (hr) |
CN (2) | CN110951670A (hr) |
AU (3) | AU2014233393B2 (hr) |
BR (1) | BR112015021993A8 (hr) |
CA (1) | CA2903596C (hr) |
ES (1) | ES2798307T3 (hr) |
HK (1) | HK1218141A1 (hr) |
HR (1) | HRP20200893T1 (hr) |
IL (2) | IL240644B (hr) |
MX (2) | MX360779B (hr) |
PL (1) | PL2970875T3 (hr) |
RU (2) | RU2718986C2 (hr) |
SG (3) | SG11201507367PA (hr) |
SI (1) | SI2970875T1 (hr) |
WO (1) | WO2014145098A1 (hr) |
ZA (2) | ZA201506155B (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2798307T3 (es) | 2013-03-15 | 2020-12-10 | Hoffmann La Roche | Composiciones de cultivo de células con antioxidantes y procedimientos para la producción de polipéptidos |
US9416181B2 (en) * | 2013-05-06 | 2016-08-16 | Abbvie Inc. | Compositions for cell culture and methods of using the same |
MA40864A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
US11254964B1 (en) * | 2016-03-15 | 2022-02-22 | Fresenius Kabi Deutschland Gmbh | Cell culture methods for increased cell viability |
US11186858B1 (en) | 2016-03-15 | 2021-11-30 | Fresenius Kabi Deutschland Gmbh | Methods for increasing biosimilarity |
SG11201809959PA (en) | 2016-05-10 | 2018-12-28 | Genentech Inc | Methods of decreasing trisulfide bonds during recombinant production of polypeptides |
CN106070537A (zh) * | 2016-07-08 | 2016-11-09 | 广东海洋大学 | 一种抑制虾黑变的抗氧化剂及其制备方法与应用 |
SG11202013191TA (en) * | 2018-07-13 | 2021-01-28 | Lonza Ag | Methods for improving production of biological products by reducing the level of endogenous protein |
WO2020091041A1 (ja) * | 2018-11-02 | 2020-05-07 | 協和キリン株式会社 | 液体培地の調製方法 |
HUP1800376A2 (hu) * | 2018-11-07 | 2020-05-28 | Richter Gedeon Nyrt | Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer |
PE20221770A1 (es) | 2019-12-06 | 2022-11-11 | Regeneron Pharma | Composiciones de proteina anti-vegf y metodos para producir la misma |
WO2023194946A1 (en) * | 2022-04-06 | 2023-10-12 | Kashiv Biosciences, Llc | An improved cell culture process for production of protein |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE266710C (hr) | ||||
US3883511A (en) | 1974-03-07 | 1975-05-13 | Rit Rech Ind Therapeut | New 6-aminopenicillanic acid derivative |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
ATE108068T1 (de) | 1987-09-23 | 1994-07-15 | Bristol Myers Squibb Co | Antikörper-heterokonjugate zur töting von hiv- infizierten zellen. |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
JP3230091B2 (ja) | 1990-06-25 | 2001-11-19 | ウェルファイド株式会社 | ヒト血清アルブミンの着色抑制方法 |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
DE69132032T2 (de) * | 1990-11-23 | 2000-12-21 | Peptech Ltd | Verzögerung, verhinderung und/oder rückgängigmachen von zellalterung |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
JPH07507446A (ja) | 1992-03-04 | 1995-08-24 | シナプティック・ファーマスーティカル・コーポレーション | タウリン及びgabaの輸送体をコードするdna並びにその使用 |
JPH07102147B2 (ja) * | 1992-03-16 | 1995-11-08 | 株式会社ミドリ十字 | ヒト血清アルブミンの着色抑制方法 |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US20080318254A9 (en) | 1997-03-10 | 2008-12-25 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
US20020012991A1 (en) * | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
AU7984498A (en) * | 1997-06-25 | 1999-01-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Serum-free cell growth medium |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1167537T3 (da) | 1999-03-30 | 2008-11-10 | Japan Tobacco Inc | Fremgangsmåde til fremstilling af et monoklonalt antistof |
DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
RU2192884C2 (ru) * | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
CA2447114A1 (en) | 2001-05-16 | 2002-11-21 | Abgenix, Inc. | Human antipneumococcal antibodies from non-human animals |
EP1404813A4 (en) | 2001-06-13 | 2004-11-24 | Genentech Inc | METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS |
SI1425389T1 (sl) | 2001-08-23 | 2012-02-29 | Genmab As | Humana protitelesa, specifična za interlevkin 15 (IL-15) |
US7371922B2 (en) * | 2002-07-31 | 2008-05-13 | The Board Of Trustees Of The University Of Illinois | Nuclear transfer with porcine embryonic stem cells |
US7282568B2 (en) | 2002-12-16 | 2007-10-16 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
US20060258841A1 (en) | 2003-01-17 | 2006-11-16 | Josef Michl | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
WO2004069172A2 (en) * | 2003-01-30 | 2004-08-19 | The Government of the United States of America as represented by the Department of Veterans Affairs | Multilineage-inducible cells and uses thereof |
US7456264B2 (en) | 2003-05-21 | 2008-11-25 | Medarex, Inc. | Human monoclonal antibodies against Bacillus anthracis protective antigen |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006047380A2 (en) | 2004-10-22 | 2006-05-04 | Amgen, Inc. | Method and media for single cell serum-fee culture of cho cells |
AU2005302516A1 (en) | 2004-10-29 | 2006-05-11 | Centocor, Inc. | Chemically defined media compositions |
WO2006089232A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking fucosyl residues |
JP2008536524A (ja) * | 2005-04-21 | 2008-09-11 | グレン エー. ゴールドスタイン, | 不妊に関連する酸化ストレス治療のためのn−アセチルシステインアミド(nacアミド) |
CN101203242A (zh) * | 2005-04-22 | 2008-06-18 | 健泰科生物技术公司 | 用cd20抗体治疗痴呆或阿耳茨海默氏病的方法 |
CA2607663C (en) * | 2005-05-19 | 2014-08-12 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
JP2009539378A (ja) | 2006-06-09 | 2009-11-19 | アントフロゲネシス コーポレーション | 胎盤環境及び幹細胞を培養するためのその使用 |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
CN101809161B (zh) | 2007-08-07 | 2014-03-12 | 中外制药株式会社 | 异种蛋白的制备方法 |
KR101280704B1 (ko) | 2007-10-12 | 2013-07-01 | 에프. 호프만-라 로슈 아게 | 다수의 핵산으로부터의 단백질 발현 |
CN101418330B (zh) | 2008-06-20 | 2012-01-04 | 华东理工大学 | 适于nso细胞大规模培养及抗体生产的无蛋白培养基 |
JP2012503487A (ja) * | 2008-09-26 | 2012-02-09 | シェーリング コーポレイション | 高力価抗体の製造 |
CN101603026B (zh) * | 2009-06-19 | 2011-01-19 | 华东理工大学 | 适于动物细胞产品生产的无动物来源低蛋白培养基 |
JP2012533548A (ja) | 2009-07-14 | 2012-12-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 組成物における黄色形成および過酸化物形成を阻害する方法 |
SG10201901417UA (en) | 2009-08-11 | 2019-03-28 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
CA2795461C (en) | 2010-04-26 | 2018-04-24 | Novartis Ag | Improved cell cultivation process |
RU2013125777A (ru) * | 2010-11-05 | 2014-12-10 | Эббви Инк. | Эффективный и экономичный скрининг добавок для создания сред определенного химического состава при культивировании клеток |
CN102093978A (zh) * | 2010-12-17 | 2011-06-15 | 上海市农业科学院 | 猪早期胚胎发育前期培养液及后期培养液 |
AR084754A1 (es) * | 2010-12-30 | 2013-06-05 | Anthrogenesis Corp | Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso |
US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
US20150267237A1 (en) * | 2012-04-24 | 2015-09-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
CN204634080U (zh) | 2012-08-20 | 2015-09-09 | 施雷德公司 | 将led光源与电浪涌隔离的系统以及包括该系统的光源 |
ES2798307T3 (es) | 2013-03-15 | 2020-12-10 | Hoffmann La Roche | Composiciones de cultivo de células con antioxidantes y procedimientos para la producción de polipéptidos |
-
2014
- 2014-03-14 ES ES14721668T patent/ES2798307T3/es active Active
- 2014-03-14 SG SG11201507367PA patent/SG11201507367PA/en unknown
- 2014-03-14 CN CN201911337799.2A patent/CN110951670A/zh active Pending
- 2014-03-14 CN CN201480014227.XA patent/CN105121628B/zh active Active
- 2014-03-14 WO PCT/US2014/029772 patent/WO2014145098A1/en active Application Filing
- 2014-03-14 AU AU2014233393A patent/AU2014233393B2/en active Active
- 2014-03-14 US US14/211,416 patent/US10017732B2/en active Active
- 2014-03-14 BR BR112015021993A patent/BR112015021993A8/pt not_active Application Discontinuation
- 2014-03-14 SI SI201431588T patent/SI2970875T1/sl unknown
- 2014-03-14 MX MX2015012875A patent/MX360779B/es active IP Right Grant
- 2014-03-14 RU RU2015144172A patent/RU2718986C2/ru active
- 2014-03-14 SG SG10201809452RA patent/SG10201809452RA/en unknown
- 2014-03-14 EP EP14721668.3A patent/EP2970875B1/en active Active
- 2014-03-14 RU RU2020111947A patent/RU2020111947A/ru unknown
- 2014-03-14 SG SG10201912621TA patent/SG10201912621TA/en unknown
- 2014-03-14 KR KR1020157028514A patent/KR102235452B1/ko active IP Right Grant
- 2014-03-14 CA CA2903596A patent/CA2903596C/en active Active
- 2014-03-14 PL PL14721668T patent/PL2970875T3/pl unknown
- 2014-03-14 EP EP20168621.9A patent/EP3712252A1/en active Pending
- 2014-03-14 JP JP2016503220A patent/JP6591395B2/ja active Active
- 2014-03-14 KR KR1020217009254A patent/KR20210037745A/ko not_active Application Discontinuation
-
2015
- 2015-08-18 IL IL240644A patent/IL240644B/en active IP Right Grant
- 2015-08-24 ZA ZA2015/06155A patent/ZA201506155B/en unknown
- 2015-09-11 US US14/852,311 patent/US10131873B2/en active Active
- 2015-09-14 MX MX2018014043A patent/MX2018014043A/es unknown
-
2016
- 2016-05-31 HK HK16106171.0A patent/HK1218141A1/zh unknown
-
2018
- 2018-06-04 US US15/997,342 patent/US10676710B2/en active Active
- 2018-08-23 ZA ZA201805630A patent/ZA201805630B/en unknown
- 2018-10-04 US US16/151,904 patent/US10829732B2/en active Active
-
2019
- 2019-03-27 JP JP2019060156A patent/JP6843911B2/ja active Active
-
2020
- 2020-03-22 IL IL273504A patent/IL273504A/en unknown
- 2020-06-04 HR HRP20200893TT patent/HRP20200893T1/hr unknown
- 2020-08-24 AU AU2020223634A patent/AU2020223634A1/en not_active Abandoned
- 2020-10-05 US US17/063,322 patent/US20210017488A1/en not_active Abandoned
-
2022
- 2022-09-14 AU AU2022231703A patent/AU2022231703A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200893T1 (hr) | Pripravci stanične kulture s antioksidansima i postupci proizvodnje polipeptida | |
HRP20191865T1 (hr) | Novi heterodimerni proteini | |
AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
PE20211214A1 (es) | Variantes de pertuzumab y su evaluacion | |
HRP20191409T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
HRP20220107T1 (hr) | Proteini koji vežu kalikrein plazme | |
IN2013MU02285A (hr) | ||
EP4295911A2 (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
RU2013152982A (ru) | Способ снижения гетерогенности антител и способ получения соответствующих антител | |
EA201791366A1 (ru) | Антитела к c5 и способы их применения | |
EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
NZ701825A (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
RU2012150346A (ru) | Улучшенная среда для культивирования клеток | |
JP2016514461A5 (hr) | ||
ES2721656T3 (es) | Anticuerpo anti-CD19 que tiene función ADCC con un perfil de glicosilación mejorado | |
AR091116A1 (es) | Anticuerpos biespecificos y sus metodos de uso | |
BR112015007319A2 (pt) | composições e métodos para produzir glicoproteínas | |
CO6241165A2 (es) | Uso de temperatura baja y/o ph bajo en el cultivo de celulas | |
AR103172A1 (es) | Reducción selectiva de residuos de cisteina en anticuerpos il-17 | |
AR055439A1 (es) | Plantas con rendimiento aumentado y metodo para elaborarlas | |
RU2015144020A (ru) | Среды для культивирования клеток и способы получения антител | |
HRP20211026T1 (hr) | Metoda za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji | |
BR112016012229A2 (pt) | métodos de produção de polipeptídeos | |
HRP20130028T1 (hr) | Rekombinantna ko-ekspresija podjedinice reduktaze vitamin k epoksida u svrhu poboljšanja ekspresije vitamin k-ovisnog proteina | |
BR112014032677A2 (pt) | ensaios rápido para ativação de célula t por medições de rna usando citometria de fluxo |